Medicine
Carbzah 4 mg/5 mL oral solution
Carbzah 4 mg/5 mL oral solution is a prescription medicine containing Carbinoxamine for oral use, marketed by IPG Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F).
Key facts
- Active ingredient (INN)
- Carbinoxamine
- Brand
- Carbzah
- Strength
- 4 mg/5 mL
- Dosage form
- Oral solution
- Route
- Oral
- Packs
- 473 mL
- Marketing authorisation holder
- IPG Pharmaceuticals
- Manufacturer
- IPG Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- R06AA08 Carbinoxamine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 June 2025
- Identifiers
- RxCUI 1010696, 2730039DailyMed set ID a845fc15-c675-4e33-840c-6a74e79d0cedNDC 71085-080Application ANDA040458
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 473 mL in 1 bottle, plastic | 71085-080-07 | IPG Pharmaceuticals | 1 June 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 March 2013 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Carbinoxamine 4 mg/5 mL oral solution.
Other strengths and forms of Carbinoxamine
Clinical summary
Carbinoxamine is a histamine-1 receptor antagonist. It is available as tablets, extended-release oral suspension and oral solution. MedsAcross supplies Carbinoxamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CarbinoxamineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Carbinoxamine Maleate Extended-Release Oral Suspension prescribing information (Neos Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Carbzah 4 mg/5 mL oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.